Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. - Wikidata - awgldk - TriplyDB

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.

http://www.wikidata.org/entity/Q34930673

about

C/EBPα Dysregulation in AML and ALL Acute Myeloid Leukemia: A Concise Review Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia Molecular Genetic Markers in Acute Myeloid Leukemia Post-remission therapy for acute myeloid leukemia Allogeneic stem cell transplantation in first complete remission The prognostic and functional role of microRNAs in acute myeloid leukemia ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia LSD1 inhibition: a therapeutic strategy in cancer?A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis CEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a Chinese population EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors.The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.Long-term follow-up of cytogenetically normal CEBPA-mutated AML C/EBPα and MYB regulate FLT3 expression in AML DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker Regulation of CDX4 gene transcription by HoxA9, HoxA10, the Mll-Ell oncogene and Shp2 during leukemogenesis The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology Sparse expression bases in cancer reveal tumor drivers.Systematic computation with functional gene-sets among leukemic and hematopoietic stem cells reveals a favorable prognostic signature for acute myeloid leukemia Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia

P2860

Q22065117-A5732016-902D-452D-847D-4A0098ABBE75 Q26766719-09EAA614-0A19-4C39-A9B1-C08DFD8F5F7C Q26776393-06EF8C56-2F2A-4E43-A5EC-DCC61F71FF52 Q26796514-B9E232CA-5735-43DC-86AE-60D3C3AAC183 Q26799606-D1660F5A-D603-4294-BF9E-C597F46B8923 Q26995867-C783A9DC-D8C3-4E11-A21D-7A43F1C02F7A Q26996818-0BC3E5D5-0475-4616-827E-33A8D88159F9 Q27693865-2E53605C-EFC8-495C-BA55-F67463EF8D8D Q27851679-A00CFC8D-4591-412F-AAE7-EB76B28A7F53 Q27853039-88CBED67-94E2-4693-9D65-1F5B7F7B273E Q28075654-1AE4479A-80C9-4757-BFEA-15E2B92E54FF Q28274561-BABE7ECB-4374-4546-8E5A-6025FF97BFCA Q28298834-F77261D9-A191-475F-8460-0F55A25714CE Q31111079-D7DD4174-D09E-4266-B825-C09DA13453BC Q33112273-E66D62A3-E5FF-4371-959A-4BBDAFD532AD Q33518516-EB862F1B-1D0D-4820-BCE0-C6DA41F0BA82 Q33555627-F65D265F-D899-44A7-8A4D-6AB32726EB38 Q33573806-58F0464B-A778-46C2-80C5-E154B095B62A Q33687080-BB83AABD-3441-40B5-B80B-9AC053FA7E17 Q33737486-CFB79C52-FA91-46F3-99C8-3AF7895EF93F Q33873844-E363B4E8-EBBB-41E3-BFF8-CD90D3DE1FA0 Q34233639-A8E8535B-6600-44FB-A759-D1542818F347 Q34425939-C22700FD-D1CB-4767-8BC2-32BF84633665 Q34433577-E470EA51-9F18-438F-975C-8050A8B047D0 Q34502042-BEC8FD17-7792-4824-B0A4-0CB7B105FA14 Q34502869-6B9584ED-7495-4D80-A925-C5D84F80A141 Q34542996-9AA06F58-F438-48E1-8AD9-9ACF33391D74 Q34548156-04F27398-30B8-43E1-9BC4-FCAB9B5331F2 Q34612599-D697A74D-84CE-4320-89EF-77CA445C2C1B Q34635511-9213C983-F54F-4C64-8A8E-2B647AF563D4 Q34655572-142EFC04-C28B-41C5-8809-0FF6599E8A58 Q34720554-C3C1DB23-1B7C-4F8E-8573-51BF00AD1BB2 Q34766998-997397D2-2C6F-4E0F-9A74-514AC7D83D30 Q35026864-4E1AA4C6-17BB-408A-A1CE-A62DB3F6A22B Q35083685-8C9522BA-9966-4B38-B943-F354D2B42D8C Q35088941-CA9CE3B3-0A93-4E70-A7B9-5F2103E214D6 Q35223635-40CD7282-CD33-4FCA-859E-5F716A94D4BD Q35265946-6BB60668-7505-43EA-9FF7-48D9513E6DA8 Q35381542-DDFD508E-3315-496B-8C83-0DAC22AF5BE0 Q35562821-0624CF91-9430-40FB-A75A-8F5B8367E674

P2860

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.

http://www.wikidata.org/entity/Q34930673

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Double CEBPA mutations, but no ...... ated with a favorable outcome.

@ast

Double CEBPA mutations, but no ...... ated with a favorable outcome.

@en

Double CEBPA mutations, but no ...... ated with a favorable outcome.

@nl

type

label

Double CEBPA mutations, but no ...... ated with a favorable outcome.

@ast

Double CEBPA mutations, but no ...... ated with a favorable outcome.

@en

Double CEBPA mutations, but no ...... ated with a favorable outcome.

@nl

prefLabel

Double CEBPA mutations, but no ...... ated with a favorable outcome.

@ast

Double CEBPA mutations, but no ...... ated with a favorable outcome.

@en

Double CEBPA mutations, but no ...... ated with a favorable outcome.

@nl

P1433

Q34930673-261F8FDC-0C5B-4866-864B-A529DA71090C

P1476

Q34930673-DEDEB955-3DD5-4C35-B7AB-B1B6C76E0319

P2093

Q34930673-4850656E-FE19-4323-9321-4F181134C743

Q34930673-4F0782EB-0A67-4778-9035-7CA9A02E2BF3

Q34930673-96E84B44-A306-4F28-AF05-5BB28B58F488

Q34930673-D88CAAE2-3788-42A0-8B0D-7970079BBD9E

Q34930673-F35F1295-A9E3-4BE7-9A97-1C87B3EBE37B

P2860

Q34930673-07C56E34-E813-4448-91A6-74FFDAA299DA

Q34930673-1976AF95-A3AC-43D5-BCF9-BB911AE917D3

Q34930673-1A525494-518A-4E6E-A561-90DB80956DB4

Q34930673-41617B00-BEC6-4B1B-BCF5-9ED5BC16C72B

Q34930673-4970D553-669B-4800-9AB3-24CE0634A80B

Q34930673-5E311E82-E329-470F-B5B3-EAF525E578F6

Q34930673-5FFBD193-6E0C-47D3-B30B-DBD7C379636A

Q34930673-63DCE20A-757A-4F99-8471-99EAB8F6BB74

Q34930673-6994E1A4-DCFC-4B98-9C93-8D6A77592DC4

Q34930673-967D4046-ADC4-4B0A-A16B-5126175C05C0

P304

Q34930673-CE01E076-F05A-48D8-A385-459672F1C9B4

P31

Q34930673-19271F34-95BB-4CA2-9867-A77AB8FC35BD

P356

Q34930673-FB1E86A7-25E9-45C1-A4B5-90DBA4C0447D

P407

Q34930673-977B3F29-4E36-4446-801C-08A69D1C9B32

P433

Q34930673-89CBAE6C-4A08-4EC1-AD47-B0A6DADBD33F

P478

Q34930673-F95AB0A7-FD38-4B59-98AF-CDB9C3E44E57

P50

Q34930673-D24C6366-E4E2-4836-832E-C9CDF21D2A19

P577

Q34930673-60B8F2E1-4D31-40D7-9844-A99CC7C85E71

P5875

Q34930673-FF5E2D5E-15FA-4195-A231-3B6BBEDC3DDB

P698

Q34930673-23FDDEDA-F703-46B7-B683-10105D06A6A3

P921

Q34930673-6CDB0DD0-311C-4DB4-AEDE-EE0E834BE07A

P932

Q34930673-72CBFE94-451A-4CB8-8427-2645C313C25D

P356

BLOOD-2008-09-179895

P1433

P1476

Double CEBPA mutations, but no ...... ated with a favorable outcome.

@en

P2093

Bas J Wouters

http://www.w3.org/2001/XMLSchema#string

Claudia A J Erpelinck-Verschueren

http://www.w3.org/2001/XMLSchema#string

Peter J M Valk

http://www.w3.org/2001/XMLSchema#string

Ruud Delwel

http://www.w3.org/2001/XMLSchema#string

Wim L J van Putten

http://www.w3.org/2001/XMLSchema#string

P2860

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Diagnosis of multiple cancer types by shrunken centroids of gene expression

CEBPA point mutations in hematological malignancies.

C/EBPalpha mutations in acute myeloid leukaemias.

Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.

C/EBPalpha and the pathophysiology of acute myeloid leukemia.

Transcriptional dysregulation during myeloid transformation in AML.

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

P304

3088-3091

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-09-179895

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23951019

http://www.w3.org/2001/XMLSchema#string

P698

19171880

http://www.w3.org/2001/XMLSchema#string

P921

P932

2662648

http://www.w3.org/2001/XMLSchema#string